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Introduction: The ovarian hyperstimulation syndrome (OHSS), although uncommon, is an
important complication of assisted reproduction because of its morbidity and possible lethal
outcome.
Objective: To verify the incidence of OHSS in public service of assisted reproduction and
review the literature.
Method: A descriptive retrospective study of patients enrolled in the Assisted Reproduction
Laboratory of Hospital Pérola Byington who had 15 or more oocytes retrieved during con-
trolled ovarian stimulation cycle, period 2010-2012. A literature search was conducted in the
databases Medline, Scopus and SciELO including articles indexed between 2010 and 2013.
Results: OHSS was observed in 17 cycles (1.9%) of 857 performed. The mean age was 33.2
years,  with a mean of 21.6 oocytes retrieved and 11.5 mature oocytes. Hospitalization and
ascites puncture was required in ﬁve cases. There was no fatal outcome. The literature sug-gests  that methods used to predict the ovarian response help to prevent OHSS, as antral
follicle count, serum estradiol and anti-mullerian hormone. Evidence indicates that stimu-
lation with GnRH antagonist and triggering with GnRH agonist, with or without vitriﬁcation
trategies for patients with high risk for OHSS.of  embryos are safe s Research conducted at Hospital Pérola Byington, São Paulo, SP, Brazil.
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Conclusion: The incidence of OHSS was found to be within the range of literature. Although
none of the approaches for the prevention of OHSS is fully effective, the majority demon-
strates a decreasing incidence in high-risk patients.
© 2013 Sociedade Brasileira de Reproduc¸ão Humana. Published by Elsevier Editora Ltda. 
Síndrome  de  Hiperestímulo  Ovariano:  incidência  em  um  servic¸o público
de  reproduc¸ão  assistida  e  revisão  da  literatura
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Introduc¸ão: A Síndrome de Hiperestímulo Ovariano (SHO), apesar de pouco frequente, é
complicac¸ão  importante na reproduc¸ão assistida devido sua morbidade e possibilidade de
desfecho letal.
Objetivo: Veriﬁcar a incidência da SHO em servic¸o público de reproduc¸ão assistida e revisar
a  literatura.
Método: Estudo descritivo retrospectivo com prontuários de pacientes matriculadas no
Laboratório de Reproduc¸ão Assistida do Hospital Pérola Byington de 2010 a 2012, que apre-
sentaram 15 ou mais oócitos aspirados durante ciclo de estimulac¸ão ovariana controlada.
Consulta nas bases de dados do Medline, Scopus e Scielo incluindo artigos indexados entre
2010  e 2013.
Resultados: SHO foi veriﬁcada em 17 ciclos (1,9%) dos 857 realizados. A média etária foi de 33,2
anos,  com média de 21,6 oócitos aspirados e 11,5 oócitos maduros. Internac¸ão foi necessária
em cinco casos. Não houve desfecho fatal. A literatura aponta que métodos empregados
para prever a resposta ovariana auxiliam na prevenc¸ão da SHO, como contagem de folícu-
los  antrais, dosagem de estradiol e hormônio anti-mulleriano. Evidências indicam que a
estimulac¸ão  com antagonista do GnRH e desencadeamento da ovulac¸ão com agonista do
GnRH, com ou sem vitriﬁcac¸ão de embriões, como estratégias seguras para pacientes com
alto risco para SHO.
Conclusão: A incidência da SHO mostrou-se dentro da variac¸ão da literatura. Embora nen-
huma das abordagens de prevenc¸ão da SHO seja totalmente eﬁcaz, a maioria demonstra
diminuic¸ão  da incidência em pacientes de alto risco.
©  2013 Sociedade Brasileira de Reproduc¸ão Humana. Publicado por Elsevier Editora
I
T
f
A
s
l
o
3
p
m
E
1
d
a
p
r
f
t
a
Considering its importance, the objective is to determine
Este é um artigo Open Access sob a licença de CC BY-NC-NDntroduction
he ovarian hyperstimulation syndrome (OHSS) remains a
eared complication, both the patient and the physician using
ssisted Reproduction Techniques (ART). The OHSS presents
ymptoms from mild to severe forms of abdominal discomfort
eading to hospitalization, and, in some cases, including fatal
utcome.1
The incidence of clinically signiﬁcant OHSS is 2 to
%. However, milder forms may develop up to 30% of
atients undergoing ART.2 The syndrome affects approxi-
ately 6,020 patients per year in the United States and
urope, with risk of death estimated between 1:450,000 and
:500,000.3,4
The pathophysiology of OHSS is complex and not yet fully
etermined. However, it involves increased capillary perme-
bility mesothelial surface of the ovaries and extravasation of
rotein-rich ﬂuid in the third space.5 Clinical manifestations
eﬂect the extent of leakage and hemoconcentration resulting
rom intravascular volume depletion.Signs and symptoms vary according to the severity of
he syndrome. It might occur only mild discomfort and
bdominal distension due to the increase in the volume ofLtda.
one or both ovaries. In more  severe forms it can be observed
the formation of ascites in varying degrees, pleural effusion
and oliguria, renal failure and death may occur as a result of
hemoconcentration and reduced perfusion of other organs
such as kidneys, heart and brain.6,7
Two types of OHSS are identiﬁed. The early onset one,
which is associated with the response after ovarian stim-
ulation, is usually self-limited if no pregnancy occurs. The
delayed form develops in ten days or more  after conception,
and in many  cases require hospitalization.8,9
Several studies indicate that the development of OHSS is
mediated by the presence of human chorionic gonadotropin
(hCG), exogenous or endogenous.5 The administration
of hCG would lead to an increased vascular perme-
ability, mediated by the receptors of vascular endothe-
lial growth factor (VEGF) present in the theca-cells and
granulosa.5,10,11 Prostaglandins, inhibin, mediators of the
inﬂammatory system and activation of the renin-angiotensin-
aldosterone system are also factors involved in the etiology of
OHSS.5,12
Este é um artigo Open Access sob a licença de CC BY-NC-NDthe incidence of OHSS in a public service of assisted repro-
duction and review relevant publications on the topic with an
emphasis on prevention.
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Method
A retrospective descriptive study in which they were con-
sulted the medical records of all patients regularly enrolled
in the Assisted Reproduction Laboratory of Hospital Pérola
Byington who  had 15 or more  oocytes aspirated during con-
trolled ovarian stimulation cycle in the period 2010-2012. Data
of the patients were recorded: age, infertility factor, type and
number of units of FSH, type of agonist/antagonist employed,
type of medication to trigger ovulation, number of oocytes
aspirated, number of mature oocytes, fertilization rate; tech-
nique of fertilization, embryo transfer, days of hospitalization,
ascites puncture; occurrence of pregnancy and mode of treat-
ment.
For the literature review were consulted the databases Med-
ical Literature Analysis and Retrieval System Online (Medline)
and Pubmed, Scientiﬁc Electronic Library Online (SciELO) and
SCOPUS. The survey covered the period from 2010 to 2012 and
used DeCS/MeSH with the syntax “[Ovarian Hyperstimula-
tion Syndrome] AND [Fertilization In Vitro].” The search result
considered original articles, systematic reviews, explanatory
reviews that address OHSS in patients undergoing in vitro fer-
tilization techniques.
Results
The incidence of ovarian hyperstimulation syndrome (OHSS)
was 1.9%. It was diagnosed in 15 patients, two of which showed
the condition in more  than one cycle, with a total of 17 cycles
with OHSS from 857 cycles performed. The age ranged 23-41
years, mean 33.2 years. Between 9 and 32 oocytes were aspi-
rated in 17 cases, averaging 21.6 oocytes aspirated and 11.5
mature oocytes (Table 1).
The hospitalization for treatment of OHSS was required in
ﬁve cases, with an average of 6.4 days. Ascite puncture was
performed in ﬁve cases (Table 2). There was no fatal outcome
in the studied cases of OHSS.
We have identiﬁed 308 articles indexed to descriptors
DeCS/MeSH in the four databases consulted. After analyzing
the manuscripts, 20 publications were selected between clin-
ical trials and systematic reviews (Table 3).
Discussion
The incidence of ovarian hyperstimulation syndrome (OHSS)
of 1.9% found in this study proved to be convergent with what
has been veriﬁed in other publications. The same occurred for
the characterization of patients with OHSS and the assisted
reproduction techniques employed.
The prophylaxis of OHSS is a multistep process, being crit-
ical for the primary prevention to recognize the risk factors
and individualize controlled ovarian stimulation (COS).31,32 It
is necessary to identify the population at risk before perform-
ing the ovarian stimulation, with the objective of minimizing
the doses without any worse reproductive outcome. Finally,
it is necessary to take the decision on the trigger ovulation
shot and achievement of embryo transfer or not, taking into 3;2  8(1):10–17
account the risks posed to the patient and the psychological,
social and economic impact of such decision.32
There is a number of well established primary risk fac-
tors for developing OHSS, including low age, history of
Polycystic Ovary Syndrome (PCOS) and personal history of
hyper-response in a previous cycle of in vitro fertilization
(IVF).12,33,34 Several risk factors and biomarkers for OHSS are
known and help to identify patients who require individu-
alized COS. However, the sensitivity and speciﬁcity of these
markers to predict hyperresponsiveness is variable.35,36
The antral follicle count (AFC) is the number of follicles
with 2 to 10 mm in diameter. It is a widely used biomarker to
predict the response of a patient under COS and determine
the risk of OHSS. It can be easily deﬁned by transvaginal ultra-
sound, ideally in the early follicular phase. A small number
of antral follicles is related to the age of the patient and may
reﬂect the ovarian reserve and so predict its answer.36–38
The dosing of Anti-Müllerian Hormone (AMH) before the
COS also proved to be a predictive factor for the develop-
ment of OHSS.5,31 Two randomized prospective cohort studies
have shown that basal AMH ≥ 3.5 ng/mL can predict the
hyper-response with high sensitivity (90.5%) and speciﬁcity
(81.3%).37,39 Moreover, the dosing of AMH  may be a better
predictor than age, basal follicle stimulating hormone (FSH),
estradiol (E2), and AFC.31,37,40 Serum measurements of E2 on
the day of ovulation triggering greater than 4,500 pg/mL are
considered predictors of risk for OHSS,5,36 although high levels
of E2 alone prove to be poor predictors.3,35,36
The presence of PCOS is considered by many  authors as
the main risk factor related to OHSS5. This is probably due
to the increased recruitment of follicles in various stages of
maturation, associated with the pathophysiology of PCOS. The
PCOS patients who have hyperinsulinemia are more  likely to
develop syndrome than patients with regular insulin. It is
believed that insulin acts as a stimulating factor for early-
stage follicles, leading to more  mature follicles, which respond
more to the presence of luteinizing hormone (LH) and human
chorionic gonadotropin (hCG).5
There is no doubt that the incidence of OHSS is related to
the ovarian stimulation regime used.5 Therefore, several pro-
tocols have been proposed with the aim of minimizing the
risk of developing this syndrome during COS. These strategies
include the use of lower doses of FSH, coasting, reduction of
the dosage of hCG in the ﬁnal oocyte maturation, cancellation
of the cycle before the hCG, cancellation of embryo transfer
and cryopreservation of all viable embryos, and the use of
GnRH agonist alternatively to hCG.34
The use of higher doses of FSH increases the risk of
hyperstimulation. Therefore, protocols with low-dose (150 IU
of FSH), independent of the patient age, using step up or
step down, occur with lower risk of OHSS.5 It is observed
increased risk of OHSS in cycles of stimulation with urinary
gonadotropins in relation to the recombinant.5 The use of
GnRH agonist protocols, particularly long protocols, lead to
increased incidence of OHSS, probably by stimulation of a large
cohort of follicles, combined with the absence of a sponta-
5neous process of luteinization.
The coasting strategy has been used as a measure of
prevention of OHSS and consists of suspending the admin-
istration of exogenous gonadotropins and postpone the
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Table 1 – Assisted reproduction technique employed and oocyte production in cases of Ovarian Hyperstimulation Syndrome (OHSS), Hospital Pérola Byington,
2010-2012.
Case Age Factor Type and Units of FSH Agonist or Antagonist of GnRH Triggering Ovulation Aspired oocytes Mature oocytes
1 41 TF + Male Betafolitropina 2100 IU e
hCG diluted 600 IU
Leuprolide Acetate
1,875 mg
Alfacoriogonado-tropina 250 mg 16 8
2 38 PCOS Folitroﬁna alfa 2200 IU e
hCG diluted 600 IU
Leuprolide Acetate
1,875 mg
hCG  urinary
5000 IU
19  8
3 39 PCOS Menotropina 1650 IU Cetrorrelix
Acetate
0,25  mg
(4 days)
Alfacoriogonado-tropina 250 mg 21 8
4 30 PCOS Folitroﬁna alfa 1650 IU Cetrorrelix
Acetate
0,25 mg
(6 days)
Alfacoriogonado-tropina 250 mg 22 15
5 37 Male Betafolitropina 2700 IU Not utilized Alfacoriogonado-tropina 250 mg 26 12
6 28 Donor Folitroﬁna alfa 2400 IU Ganirelix Acetate
0,25 mg
(4 days)
hCG  urinary
5000 IU
19  10
7 33 PCOS Betafolitropina 700 IU
and Menotropina 450 IU
Not utilized hCG urinary
5000 IU
23  10
8 36 TF + Male Folitroﬁna alfa 1575 IU
and Betafolitropina 1200
IU
Leuprolide Acetate
1,875 mg
hCG  urinary
5000 IU
31  8
9 37 Male Betafolitropina 2200 IU Leuprolide Acetate
1,875 mg
Alfacoriogonado-tropina 250 mg 21 8
10 37 Male Betafolitropina 1200 IU
and Folitroﬁna alfa 1125
IU
Leuprolide Acetate
1,875 mg
Alfacoriogonado-tropina 250 mg 19 8
11 30 TF Betafolitropina 2200 IU Leuprolide Acetate
1,875 mg
Alfacoriogonado-tropina 250 mg 25 16
12 29 PCOS Folitroﬁna alfa 750 IU and
Betafolitropina 350 IU
Cetrorrelix Acetate
0,25 mg
(3 days)
Acetato de Leuprolide
3,75 mg
9  8
13 30 PCOS Betafolitropina 1100 IU Triptorrelina Acetate
3,75 mg
Alfacoriogonado-tropina 250 mg 32 12
14 39 UI Menotropina 2700 IU Leuprolide Acetate
1,875 mg
Alfacoriogonado-tropina 250 mg 19 15
15 32 UI Folitroﬁna alfa 1650 IU Leuprolide Acetate
1,875 mg
hCG  urinary
5000 IU
23  11
16 26 Fertility Preservation Folitropina alfa IU+
lutropina alfa 1350 IU
Cetrorrelix Acetate
0,25 mg
(4 days)
Triptorrelina Acetate
3,75 mg
27  24
17 23 Fertility Preservation Menotropina 2475 IU Ganirelix Acetate
0,25 mg
(7 days)
Alfacoriogonado-tropina 250 mg 16 15
PCOS, polycystic ovary syndrome; UI, unexplained infertility; TF, tubal factor; hCG, human chorionic gonadotropin; GnRH, gonadotropin-releasing hormone; IU, internacional unit; mg, milligram.
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Table 2 – Results of assisted reproduction technique employed, days of hospitalization and treatment of cases of Ovarian
Hyperstimulation Syndrome (OHSS), Hospital Pérola Byington, 2010 - 2012.
Case RA technique Fertilization
rate (%)
Nr of embryos
transfered
DH puncture
ascites
Gestac¸ão  Tratamento
1 IVF 60,0 2  6 No Yes albumin furosemide, heparin,
bromocriptine, progesterone
2 OCP 62,5 Suspended 0 No No bromocriptine
3 IVF 100,0 2 0 No Yes symptomatic
4 ICSI 67,0 Suspended 3 No No hyperproteic dietary, hydration,
albumin, furosemide,
bromocriptine
5 ICSI + TESE 83,0 3 0 No No symptomatic
6 IVF + ICSI 100,0 2 0 No Yes symptomatic
7 ICSI 78,0 1 0 No Yes bromocriptine
8 ICSI 37,1 1 0 No No bromocriptine
9 ICSI 75,0 Suspended 0 No No symptomatic
10 ICSI 75,0 3 4 Yes No hyperproteic dietary, albumin,
progesterone
11 IVF 88,0 2 12 Yes Yes hyperproteic dietary, albumin,
progesterone
12 OCP − - 0 No No bromocriptine
13 ICSI 50,0 Suspended 0 No No bromocriptine
14 ICSI 60,0 3 0 No No hyperproteic dietary,
bromocriptine, hidratation
15 OCP − - 0 No No symptomatic
16 OCP − - 7 No No hyperproteic dietary, hidratation,
albumin, furosemide,
Bromocriptine
17 OCP − - 0 No No symptomatic
cyte IVF, in vitro fertilization; TESE, testicular sperm extraction; OCP, oo
hospitalization.
application of hCG until estradiol levels are below a value
considered safe.28 In a recent retrospective study that evalu-
ated 2,948 patients, it was conducted coasting on 327 women
who  had three follicles ≥ 15 mm and E2 ≥ 1635 pg/mL, get-
ting OHSS incidence of 10.4%, equivalent to 1.15% of the total
cycles IVF/ICSI of that center28. It was observed in this sub-
group of patients factors that predict moderate to severe OHSS,
as the combination of the number of retrieved oocytes and
the amount of E2 on the day of hCG, beside the presence of
multiple gestations.28
The trigger with hCG has been used as the gold standard
in assisted reproduction techniques, to be clinically approved
and highly effective. However, OHSS is still observed despite
a lower dose than normally used of 10,000 IU of hCG. The
triggering of ﬁnal oocyte maturation with hCG is the main fac-
tor associated with the development of OHSS, and therefore
alternatives such as the use of GnRH agonists or recombinant
LH can be used to promote the maturation of oocytes and
reduce the risk of hyperstimulation.5
Lin et al. (2011), have compared the triggering with 4,000
IU of urinary hCG versus 6,000 IU of hCG, ﬁnding an effect of
the ﬁnal oocyte maturation similar in both groups of patients
with moderate to intense oocyte response. However, there was
no difference in the occurrence of OHSS in both groups and
patients who received higher doses of hCG showed higher
24pregnancy rate (65.3% vs. 35%, p = 0.004).
In an attempt to establish the minimum dose of hCG neces-
sary to promote the ﬁnal oocyte maturation, Chen et al. (2013)
have developed a study in which six women at high risk ofcryopreservation; ICSI, intracytoplasmic sperm inject; DH, days of
developing OHSS received triggering with 2,000 IU of urinary
hCG. There were no cases of OHSS with the dose applied, and
only one patient had the embryo transfer cancelled and the
embryos were frozen with subsequent transfer. In this study,
we observed satisfactory reproductive outcomes with the dose
used. The average number of oocytes collected was higher
than 14, with fertilization rate greater than 77%. Although the
sample was small, the results pointed to a tendency to use
lower doses of hCG in patients hyper-responders.30
Recent review assessed the association of the FSH dose
to trigger with hCG, called “FSH co-trigger” as a strategy to
prevent OHSS. The combination of a low dose of FSH to hCG
triggering appears to reduce the incidence of OHSS, but the
results are still preliminary and there are potential confound-
ing factors.27
It has been shown that the use of GnRH agonist to trig-
ger ovulation, which is only possible with the protocols with
antagonist, leads to a lower risk of OHSS and ensures proper
oocyte maturation, requiring modiﬁcation of the luteal phase
support.41,42 This luteal support can be accomplished with
hCG at low doses, in bolus on the day of the oocytes collec-
tion. It is also used intense luteal support with progesterone
and estradiol IM or, alternatively, with recombinant LH.25,43
Papanikolaou et al. (2011) compared the use of GnRH ago-
nist with low doses of hCG to trigger ovulation in protocols
with both agonist and antagonist. The dose of hCG consid-
ered low was 250 mcg  of recombinant hCG or 3300-5000 UI
of urinary hCG. The trigger with GnRH agonist (Triptorelin
0.2 mg,  0.5 mg  buserelin and leuprolide 1 mg)  is only possible
r e p r o d c l i m . 2 0 1 3;2  8(1):10–17 15
Table 3 – Summary of publications on the Ovarian Hyperstimulation Syndrome (OHSS).
Author Year Summary
Yousse et al.13 2010 The use of dopamine agonist as a prophylactic treatment for patients at risk for OHSS reduces
the incidence, but not its severity, without compromising the results of pregnancy.
Griesinger et al.14 2010 Protocol with antagonist, agonist shooting and cryopreservation of all 2 Pronuclear zygotes is
effective and reduces OHSS.
Venetis et al.15 2010 Use of intravenous albumin has no effective action in preventing OHSS.
Busso et al.16 2010 Use of dopamine agonist appears to prevent moderate and severe OHSS, with better effect in
patients who did not achieve clinical pregnancy.
Papanikolau et al.17 2011 Use of minidoses of hCG or GnRH agonist as shooting to trigger ovulation, conduct face the ET
or glazing.
Hosseini et al.18 2011 Effectiveness of cabergoline in preventing OHSS, reducing its incidence.
Tehraninejad et al.19 2011 Prophylaxis with low dose of cabergoline was more effective than albumin in preventing OHSS
in high risk patients.
Pundir et al.20 2011 Meta-analysis suggests that GnRH antagonist protocol reduces the risk of OHSS in patients
with PCOS.
Radesic et al.21 2011 Oocyte maturation strategy employing a single dose of GnRH and hCG
Sansone et al.22 2011 Several strategies for the prevention of OHSS reduce the incidence of high risk patients are not
fully effective in preventing OHSS in all cases.
Bodri et al.23 2011 Use of GnRH agonist and antagonist in IVF cycles has similar rates of oocytes and current
pregnancy.
Hasum et al.5 2011 Absolute prevention of OHSS is not possible while the pathogenesis is not completely known.
Lin et al.24 2011 Low doses of hCG (4,000 IU and 6,000 IU) as a trigger for ﬁnal maturation of the oocyte in
IVF-ICSI cycles have similar rates of oocyte maturation.
Humaidan et al.25 2011 Low dose of hCG after the normalization trigger agonist reproductive outcome and minimizes
the occurrence of OHSS in patients at high risk.
Fiedler et al.26 2011 Recognition of risk factors and prevention of OHSS and use of individualized protocols COS
Rosen et al.27 2011 FSH co-trigger (bolus of FSH associated with hCG) can prevent OHSS, but the results are
preliminary.
Aljawoan et al.28 2012 Combination of number of oocytes and value of estradiol on the day of hCG provides moderate
and severe OHSS in patients undergoing coasting.
Pietrowski et al.29 2012 Implication of VEGF and VEGF in the OHSS
Chen et al.30 2013 Minimum dose of 2,000 IU of urinary hCG as a trigger in agonist long protocol as prevention of
OHSS in hyper-responders.
OHSS, ovarian hyperstimulation syndrome; PCOS, polycystic ovary syndrome; IU, international unit; GnRH, gonadotroﬁn-releasing hormone;
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n a protocol with antagonist. It has been observed that the
se of agonist to trigger ovulation minimizes the risk of OHSS,
nsuring proper oocyte maturation. The use of hCG, although
nsuring the function of the corpus luteum, may cause hyper-
timulation, even at low doses.44,45
Griessinger et al. (2010) have studied 51 patients at risk
or OHSS, all subjected to stimulation with antagonist proto-
ol and subsequent ovulation triggering with GnRH agonist in
ombination with cryopreservation of all pronuclear zygotes
n phase 2. Only one patient (2%) developed severe OHSS and
here was 5% of moderate OHSS, with cumulative live birth
ate of 37.3%. This strategy proved to be effective and safe
ay to reduce the risk of OHSS, maintaining good reproductive
utcomes.14
In recent meta-analysis that analyzed 1,024 oocytes donors
ndergoing ovarian stimulation with antagonist or agonist
nRH were observed rates of oocytes retrieved and clinical
regnancy similar in both groups. There was no difference in
he incidence of OHSS between them, although the authors
ttribute to the limited sample size and the fact that the induc-
ion of oocyte maturation end with hCG has been made in
ost studies reviewed.23
Another possibility for preventing OHSS and its severity
eduction is the use of dopamine agonist.46,47 In a systematic chorionic gonadotropin; FIV, in vitro fertilization; COS, controlled
-stimulating hormone.
review and meta-analysis of randomized trials, the data
suggested that cabergoline reduces the risk of moderate and
severe OHSS, with no statistically signiﬁcant difference in the
rates of birth, clinical pregnancy or abortion, suggesting that
endometrial angiogenesis would not be affected by the use of
dopaminergic.46,47 It was observed that the dopamine agonist
Cabergoline inactivates the receptor of the vascular endothe-
lial growth factor (VEGF r2) preventing the increase of vascular
permeability and justifying its use in the prevention of OHSS.48
A placebo-controlled double-blind randomized multicenter
trial has evaluated the use of quinagolide, dopamine agonist
not derivative of ergotamin. It was compared using three oral
doses of 50, 100 and 200 mg/day, beginning on the day of hCG
for 17 to 21 days. It has been found that the incidence of moder-
ate to severe early OHSS was signiﬁcantly lower in the groups
that received quinagolide compared with placebo, with a dose-
dependent effect. The use of dopamine agonist did not affect
reproductive outcome, with a protective effect of OHSS higher
in patients who have not become pregnant.11
Systematic reviews and meta-analyzes have evaluated the
oral use of cabergoline, at doses of 50, 100 and 200 mg,  with
another study comparing patients who used 20 g of intra-
venous albumin 20% and another group using 0.5 mg  of
cabergoline per day from the ﬁrst day after oocyte retrieval for
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7 to 14 days, reducing the risk of moderate to severe OHSS in
high risk patients. It was concluded that the use of cabergoline
was superior to the use of intravenous albumin to reduce the
risk of OHSS, and that there was no difference in the occur-
rence of OHSS in patients who received albumin and those
who  did not receive.9,15,19
Other research indicates that the use of acetylsalicylic acid
at the dose of 100 mg/day in patients at risk of developing
OHSS can be useful in the prevention, because it reduces
platelet activation related to the concentration of circulating
VEGF and thrombogenic risk that stems from the OHSS.49,50
The current lack of a fast and efﬁcient therapy that
promptly resolves electrolyte imbalance of patients makes
prevention of OHSS crucial. The cases of mild ovarian hyper-
stimulation does not require treatment and the moderates
require outpatient clinic monitoring and laboratory tests, not
forgetting the possibility of progression to the severe form.
Severe cases require hospitalization, often in intensive care
units.22
Due to the pathophysiology of hemoconcentration result-
ing from OHSS, there is a hypercoagulability, increasing
platelets, ﬁbrinogen and coagulation factors V, VI, VII, and
subsequent increased risk of thrombosis. In addition, there
are elevated transaminases, hyperkalemia, hyperglycemia by
increasing cortisol, inversion of the albumin/globulin and
metabolic acidosis. Therapy should therefore emphasize the
clinical support in an attempt to avoid the consequent
dysfunction syndrome.22 In relation to the ascites, the intra-
venous administration of 50 g of albumin may decrease 800 ml
of additional vascular ﬂuid in 15 minutes, it is recommended a
dose of 50 to 100 mg  a day, considering the half life of albumin
from 17 to 20 days.22
Conclusion
The incidence of ovarian hyperstimulation syndrome (OHSS)
found in the Service of Human Reproduction of Hospital Perola
Byington proved to be within the range suggested by the litera-
ture. The characterization of patients with OHSS and assisted
reproduction techniques employed did not differ from that
described in other studies. The literature has evaluated meth-
ods of preventing OHSS. Although none of the approaches is
so far fully effective, the majority demonstrates a decreasing
incidence in high-risk patients.
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